4/A: Rhythm Pharmaceuticals Executive Corrects Stock Option Exercise Details in Amended SEC Filing
SEC Form 4 Amendment
Rhythm Pharmaceuticals' Chief Technical Officer, Joseph Shulman, amended a previous SEC filing to correct the number of stock options exercised on February 9, 2024.
Summary
- Joseph Shulman, Chief Technical Officer of Rhythm Pharmaceuticals, filed an amended Form 4 with the SEC.
- The amendment corrects the number of stock options exercised on February 9, 2024.
- The original filing incorrectly stated that 69,190 options were exercised, but the correct number was 69,160.
- The amended filing reports the exercise of 65,175 options at $21.38 per share and 3,985 options at $6.80 per share.
- Following these transactions, Shulman directly owns 74,430 shares of common stock.
Sentiment
Score: 7
Explanation: The document is a routine correction of a previous filing, indicating a neutral to slightly positive sentiment due to the company's adherence to regulatory requirements.
Industry Context
This type of filing is standard for executives exercising stock options in publicly traded companies. It provides transparency into insider transactions.
Comparison to Industry Standards
- The filing is consistent with standard SEC reporting requirements for insider transactions.
- Many executives at publicly traded companies exercise stock options as part of their compensation packages, and these transactions are typically disclosed via Form 4 filings.
- The correction of the error in the original filing demonstrates the importance of accurate reporting and compliance with SEC regulations.
Stakeholder Impact
- The filing provides transparency to shareholders regarding executive stock transactions.
- The correction of the error ensures accurate information is available to the public.
Key Dates
| Date | Description |
|---|---|
| 02/09/2024 | Date of the stock option exercises. |
| 02/13/2024 | Date of the original Form 4 filing which contained an error. |
| 07/27/2020 | Date of grant for some of the stock options exercised. |
| 02/08/2022 | Date of grant for some of the stock options exercised. |
| 07/26/2030 | Expiration date for some of the stock options exercised. |
| 09/25/2024 | Date of the Power of Attorney document. |
| 11/13/2024 | Date of the amended Form 4 filing. |
Keywords
SEC Filing, Form 4, Stock Options, Rhythm Pharmaceuticals, Joseph Shulman, Executive Compensation, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.